Express Scripts (ESRX) Looks to Battle EpiPen with New Program; Leerink Affirms at 'Market Perform' (MYL)
- Wall St. set to open lower, weighed down by GE
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
- Pre-Open Stock Movers 10/21: (ALKS) (RAI) (PFPT) (MSFT) Higher; (SGY) (TWLO) (RRGB) Lower (more...)
- Oil rises on Russia's output freeze commitment
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Leerink affirms Express Scripts (Nasdaq: ESRX) with a Market Perform rating and $80 price target after the company announced the launch of its Diabetes Care Value Program, the industry's most comprehensive approach to improve pharmacy care while controlling plan costs for people with diabetes.
The firm commented,
This morning ESRX announced the launch of a new "Diabetes Care Value Program," which will guarantee "per-patient spending caps" that ESRX is stating will result in average 2017 diabetes drug spend that is half of what the industry is currently forecasting for commercial payers. The bio-similar Basaglar will be added as a preferred product to ESRX' National Preferred Formulary, alongside the originator product Lantus. In our view ESRX is taking a more conservative & cautious approach than is CVS with regard to Lantus. ESRX seems to be giving plan sponsors the option to either use the bio-similar or Lantus depending on their preference and desire to reduce costs. We view this announcement as a response to the EpiPen saga, with ESRX clearly stating that it is their goal to improve drug tend across this high cost therapeutic category.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades PayPal (PYPL) to Buy Following 'Solid' Q3 Results
- Microsoft (MSFT) PT Lifted to $68 at Nomura
- Jefferies Raises Price Target on ICON plc (ICLR) to $87.50; Reiterates Hold
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!